News | Stroke | August 15, 2022

Ochsner and Tulane Collaboration Uncovers What Happens to Genes Inside Artery Plaques to Trigger Strokes

Researchers at Ochsner Health and Tulane University School of Medicine have identified the genes that become active in carotid arteries when plaque rupture causes a stroke.

Getty Images


August 15, 2022 —  Researchers at Ochsner Health and Tulane University School of Medicine have identified the genes that become active in carotid arteries when plaque rupture causes a stroke. The work, published in Scientific Reports, was made possible by acquiring samples closer to the time of the stroke than previously possible. The results provide a picture of what the cells in the plaque are doing near the moment they induce a stroke. 

Cardiovascular disease is the leading cause of death globally, responsible for an estimated 17.9 million deaths annually and is often the result of plaques that build up in the arteries. When these plaques burst, they can release material into the bloodstream that blocks oxygen from reaching the heart or brain. There is no way to determine precisely when a plaque will rupture. 

Previous studies have relied on carotid artery samples obtained after the patient’s death or months after the stroke or heart attack. This either limits the information that can be obtained or misses events that occur only at the time of rupture. For the first time, the current study sequenced the RNAs in plaques from patients who had experienced a stroke within two to five days. In doing so, the team created a picture of the RNAs active closer to the time of rupture than previously possible. 

The investigators found that plaques that rupture have increased inflammation coupled with processes that would cause the loss of a portion of the plaque that protects against rupture, known as the fibrous cap. Surprisingly, the researchers found that ruptured plaques had increased B-cell markers, a white blood cell whose role in plaque rupture has not previously been appreciated. 

Carotid artery blockage is a common cause of some ischemic strokes, which happens when the blood supply to part of the brain is interrupted, preventing brain tissue from getting necessary oxygen and nutrients. Because the mechanisms that lead to some strokes and most heart attacks involve the same plaque rupture events, these findings also have implications for heart disease. 

“Inflammation is a known risk factor in atherosclerosis, leading to stroke and heart attacks,” said Hernan Bazan, MD, the John Ochsner Endowed Professor for Cardiovascular Innovation at Ochsner Health. “Carotid and coronary plaques develop a protective cap that, for unclear reasons, thins, making strokes and heart attacks more likely.” 

Study senior author Cooper Woods, PhD, Associate Professor of Physiology and Medicine at Tulane University School of Medicine, emphasizes, “Identifying the genes that promote this thinning gives us new targets for therapeutics and diagnostics to prevent heart attacks and strokes.” 

The National Institutes of Health and the Endowed John Ochsner Professorship in Cardiovascular Innovation support the research. Dr. Bazan was appointed as John Ochsner Chair in Cardiovascular Innovation last year, a position created following the death of nationally renowned cardiovascular surgeon Dr. John Ochsner to honor his legacy and impact the field of medicine. Dr. Bazan carries innovation in atherosclerotic mechanisms and acute carotid and stroke clinical research through the position. This support will continue through at least 2026. 

A Nature journal, Scientific Reports, is the 5th most-cited journal in the world, with more than 696,000 citations in 2021. The full study is online at https://www.nature.com/articles/s41598-022-17546-9

To learn more about the Endowed John Ochsner Professorship in Cardiovascular innovation: https://research.ochsner.org/research-announcements/2021/johvi 


Related Content

News | Cardiovascular Clinical Studies

Nov. 10, 2025 —Genomics, a science-led techbio company, has today announced new research that suggests polygenic risk ...

Home November 12, 2025
Home
News | Cardiovascular Clinical Studies

Oct. 21, 2025 – AskBio Inc., a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG ...

Home October 21, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 25, 2025 — Merck, known as MSD outside of the United States and Canada, has announced that new clinical trial and ...

Home August 25, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 18, 2025 — (Newswise) It’s often mistaken for a heart attack, but Takotsubo cardiomyopathy — previously known as ...

Home August 21, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 20, 2025 — A major international study published in Atherosclerosis* has found that routinely testing for ...

Home August 20, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 4, 2025 — Marea Therapeutics, Inc., a clinical-stage biotechnology company that develops next-generation medicines ...

Home August 04, 2025
Home
News | Cardiovascular Clinical Studies

July 16, 2025 — Medtronic has announced that the first patient has been enrolled in the PEripheral Onyx Liquid Embolic ...

Home July 22, 2025
Home
News | Cardiovascular Clinical Studies

June 11, 2025 — Bayer and the Broad Institute have have extended their research collaboration of 10 years by an ...

Home June 11, 2025
Home
News | Cardiovascular Clinical Studies

May 27, 2025 — Despite scientific advances in cardiovascular care, people in living in rural areas and other communities ...

Home May 27, 2025
Home
News | Cardiovascular Clinical Studies

May 20, 2025 — Shockwave Medical, Inc., part of Johnson & Johnson MedTechhas announced the 30-day primary endpoint ...

Home May 21, 2025
Home
Subscribe Now